Table 1.

Clinical and demographic features of 59 systemic lupus erythematosus participants by remission status at follow-up visit

	Remission status
	Yes	No	P-value
N	19	40
Female, n (%)	18 (94.74)	34 (85.00)	0.52
Self-reported race, n (%)			0.79
White	1 (5.26)	6 (15.00)
Black	3 (15.79)	6 (15.00)
Asian	7 (36.84)	11 (27.50)
Other	0 (0.00)	2 (5.00)
Multiple racesa	1 (5.26)	2 (5.00)
Not reportedb	7 (36.84)	13 (32.50)
Hispanic, n (%)	7 (36.84)	15 (37.50)	1.00
Age at diagnosis (years), mean (sd)	35.68 (16.34)	27.05 (10.57)	0.02
Age at baseline flare visit (years), mean (sd)	40.68 (13.64)	35.88 (12.20)	0.18
Days between visits, median [IQR]	96.00 [57.00, 267.50]	78.50 [48.50, 163.25]	0.48
SELENA SLEDAI, mean (sd)
Baseline	11.42 (5.65)	11.53 (5.85)	0.95
Follow-up	0.00 (0.00)	5.72 (4.08)	< 0.001
SLEDAI Proteinuria, n (%)
Baseline	8 (42.11)	17 (42.50)	1.00
Follow-up	0 (0.00)	6 (15.00)	0.19
Medications at follow-up (yes/no), n (%)
Prednisone	15 (78.95)	31 (77.50)	1.00
Hydroxychloroquine	17 (89.47)	32 (80.00)	0.59
Mycophenolate	7 (36.84)	15 (37.50)	1.00
Azathioprine	0 (0.00)	7 (17.50)	0.13
Belimumab	1 (5.26)	5 (12.50)	0.69
Cyclophosphamide	1 (5.26)	3 (7.50)	1.00
Solumedrol	1 (5.26)	0 (0.00)	0.70
Rituximab	1 (5.26)	3 (7.50)	1.00
Tacrolimus	0 (0.00)	2 (5.00)	0.82
Methotrexate	3 (15.79)	5 (12.50)	1.00

Remission defined as SLEDAI = 0 at follow-up visit

IQR, interquartile range; sd, standard deviation; SLE, Systemic Lupus Erythematosus; SELENA SLEDAI, SLE Disease Activity Index—the Safety of Estrogens in Lupus Erythematosus: National Assessment trial

^aAdditional race categories not solely indicated by participants included American Indian and Pacific Islander

^bMajority of participants not reporting race identified as Hispanic